Sera (SERA) Q2 2026 Earnings Call Transcript
Sera Prognostics (SERA) reported Q2 2026 revenue of $30,000, up from $17,000 last year, with a net loss of $9.1 million. The company exceeded its payer engagement goal, reaching over 20 states, and launched four commercial partnership programs. Clinical data showed a 22% reduction in NICU admissions and a 30% reduction in neonatal morbidity among first-time mothers. Management expects cash to fund operations through 2029.
How this was made
The 30-second read
Why it matters
Earnings data provide fresh insight into the company's cash position and loss trajectory, informing short- to medium-term trading decisions.
Market read
First earnings disclosure for SERA Q2 2026, offering new financial metrics and commercial progress updates.
What to watch
Potential upside if payer contracts accelerate or if additional states adopt Medicaid coverage.
Background
Sera Prognostics reported Q2 2026 results, focusing on commercial expansion and clinical validation of its PreTRM test.
Ticker impact
Q2 2026 earnings release showing $30,000 revenue, $9.1M net loss and $80.3M cash runway to 2029.
Potential slight downside pressure as loss exceeds expectations, but cash cushion may limit sell-off.
First report of earnings provides new data; loss per share $0.18 and cash position are key metrics for traders.
Market effects
Highlights commercial rollout challenges for prenatal diagnostics and potential payer adoption trends.
Illinois Medicaid coverage could spur similar state-level reimbursement actions.
European CE marking timeline shift may affect international market entry timing.
Counterpoint
Despite cash runway, continued net losses and modest revenue suggest valuation risk.
Key entities
- CompanySera Prognostics, Inc.
Developer of the PreTRM prenatal test.
- ExecutiveEvguenia Lindgardt
President and CEO of Sera Prognostics.
